Table 2 Clinical success rates by study population at the test-of-cure visit
Tigecycline CE population N = 209 (%) | Comparator CE population N = 196 (%) | Difference (Tigecycline vs Comparator)† (95% CI) | |
|---|---|---|---|
Clinical diagnoses* | |||
Deep soft tissue infections | 114/150 (76.0) | 103/132 (78.0) | -2.0 (-12.6, 8.5) |
Major abscess | 30/36 (83.3) | 34/43 (79.1) | 4.3 (-15.5, 24.0) |
Infected ulcers | 17/22 (77.3) | 15/20 (75.0) | 2.3 (-28.3, 32.9) |
Other populations | |||
Diabetes mellitus | 46/60 (76.7) | 46/66 (69.7) | 7.0 (-10.0, 24.0) |
Peripheral vascular disease | 20/27 (74.1) | 16/20 (80.0) | -5.9 (-34.4, 22.5) |
Prior antibiotic failure | 27/35 (77.1) | 26/34 (76.5) | 0.7 (-22.1, 23.5) |